Phase 2 Lymphoma Trial, Recruiting NCT07372352 Sponsor: The First Affiliated Hospital of Soochow University Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT07372352
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a type of blood cancer called peripheral T-cell lymphoma that has come back or stopped responding to at least one round of treatment
  • People who are 18 years of age or older
  • People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scoring system (confirm with trial site)
  • People who have at least one tumour that is large enough to be measured on a CT or MRI scan, meeting specific size requirements
  • People whose blood counts, heart function, kidney function, and liver function all meet minimum levels set by the trial (confirm with trial site for exact values)
  • Women who could become pregnant must have a negative pregnancy test before joining, and all participants must agree to use effective contraception during the treatment period and for one year afterwards
  • People with a life expectancy of more than 3 months
  • People who are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • People who have had major surgery or a serious physical injury within 2 weeks before enrolment, or who have not yet recovered from its effects
  • People who have had another type of cancer within the past 3 years, except for certain types of skin cancer, early-stage bladder cancer, or early-stage cervical or prostate conditions that have been fully treated and cured
  • People who have had a stroke or bleeding in the brain within the past 3 months
  • People with serious heart conditions (such as heart failure, a recent heart attack within 6 months, or unstable heart rhythm or chest pain) or serious lung conditions (such as severe breathing problems or a history of significant bronchospasm)
  • People with HIV infection, or hepatitis B or hepatitis C that is currently active and not under control
  • People with an active infection that cannot be controlled
  • People who are currently pregnant or breastfeeding
  • People with any other life-threatening illness or organ problem that the medical team considers too great a risk for participation
  • People whose body may not be able to properly absorb or process the study medications (confirm with trial site)
  • People whose lymphoma has spread to the brain or spinal cord
  • People with any other condition that the trial doctor believes would make safe or full participation difficult, or that could affect how the trial results are interpreted

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-512-67781831

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The First Affiliated Hospital of Soochow University
Registry
ClinicalTrials.gov
Start date
15 January 2026
Est. completion
15 January 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR) after 6 treatment cycles

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov